Literature DB >> 3621785

Interaction between warfarin and propafenone in healthy volunteer subjects.

R E Kates, Y G Yee, E B Kirsten.   

Abstract

The effect of propafenone on the pharmacokinetics and pharmacologic effects of warfarin was studied in healthy normal male volunteer subjects. Each drug was administered alone for 1 week followed by a combined administration for 1 additional week. Blood samples were analyzed for propafenone and warfarin concentrations and the effect of each treatment on the prothrombin time was assessed. The concurrent administration of warfarin did not produce any changes in the absorption or disposition kinetics of propafenone. Concurrent propafenone administration did lead to a reduction in the clearance of warfarin, resulting in an average increase of 38% in the mean steady-state plasma warfarin concentration. During the combined therapy phase, the prothrombin time increased significantly (P less than 0.01) from the "warfarin alone" phase. We conclude from this study that the concomitant administration of propafenone and warfarin may lead to an enhanced anticoagulant effect that may require a reduction in the warfarin dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3621785     DOI: 10.1038/clpt.1987.152

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 2.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

Review 3.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 4.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 5.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 6.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 7.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

8.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  Successful treatment of propafenone, digoxin and warfarin overdosage with plasma exchange therapy and rifampicin.

Authors:  Sule Unal; Benan Bayrakci; Umit Yasar; Tevfik Karagoz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 10.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.